Search results for " Radiotherapy"

showing 10 items of 156 documents

Fogging effect correction of Gafchromic HD-V2 film response for its use in high-dose radiotherapy

2020

GAFChromic® HD-V2 film is a reliable dose measurement device, thin, flexible, inexpensive, simple to use and easy to analyze. The response in terms of net absorbance with respect to absorbed dose was found to be linear in a large dose range, which supports the feasibility of using the film dosimeters in many applications, such as radiotherapy. For its use, a "fogging" effect must be take into account since film response changes with time. To determine a calibration curve valid for any time, fogging effect was investigated for more than 400 days. A correction procedure allows the use of HD-V2 film dosimeters in high-dose radiotheraphy, as brachytherapy, and quality assurance (QA) procedures.

Materials scienceDosimeterFoggingbusiness.industryCalibration curveSettore ING-IND/20 - Misure E Strumentazione Nuclearimedicine.medical_treatmentBrachytherapydosimetry GAFChromic film gamma radiation radiotherapy030218 nuclear medicine & medical imagingRadiation therapy03 medical and health sciences0302 clinical medicine030220 oncology & carcinogenesisAbsorbed dosemedicineDosimetrybusinessQuality assuranceBiomedical engineering
researchProduct

Radiobiological characterization of human tumor cell multilayers after conventional and particle irradiation.

2006

The goal of this study was to establish planar multilayers from human tumor cells (WiDr and SiHa) as a model for irradiation of solid tumors. In addition to using conventional X rays (250 kV) as a reference standard, multilayers were tested for their suitability in cell survival studies with heavy-ion irradiation ((12)C(6+)) in the plateau and the extended Bragg peak with a scanned ion beam. Multilayers of both cell lines showed decreased survival compared to the corresponding monolayers after both X and heavy-ion irradiation. This multicellular sensitization effect is in contrast to the multicellular resistance or contact effect commonly described in the literature. Flow cytometry measurem…

Materials scienceIon beamCell SurvivalCellBiophysicsNanotechnologyBragg peakHeavy Ion RadiotherapyX-Ray TherapyRadiation DosageFlow cytometryCell Line TumorSpheroids CellularMonolayermedicineHumansRadiology Nuclear Medicine and imagingIrradiationRadiationmedicine.diagnostic_testRadiobiologyDose-Response Relationship RadiationHuman tumormedicine.anatomical_structureTreatment OutcomeCell cultureBiophysicsRadiation research
researchProduct

Improving bleeding detector features for electron intraoperative radiotherapy

2019

Abstract Purpose The aim of this work is to improve the potential bleeding detection during intraoperative radiotherapy with linac polymethyl methacrylate applicators (PMMA), based on one previously developed. The improvements carried out have been focused on: i) minimizing the impact of the detector on the visual through the plastic applicators and ii) avoiding the asymmetry in the detection capability when the applicator is tilted. Methods Simulations have been made to select the geometry that provides a reduced visual impact on the applicator as well as allowing an independent response with the tilting angle of the applicator. A low-noise circuit for signal conditioning has been develope…

Materials scienceRadiotherapybusiness.industryOrientation (computer vision)Capacitive sensingDetectorBiophysicsGeneral Physics and AstronomyElectronsHemorrhageGeneral MedicineElectronLinear particle accelerator030218 nuclear medicine & medical imagingIntraoperative Period03 medical and health sciences0302 clinical medicineOptics030220 oncology & carcinogenesisRadiology Nuclear Medicine and imagingParticle AcceleratorsbusinessIntraoperative radiotherapyQuality assuranceSignal conditioningPhysica Medica
researchProduct

Coronectomy - An alternative approach to remove impacted teeth in oncological patients.

2018

Background Coronectomy involves the section of the tooth crown leaving the roots in the socket. Possibility of inferior alveolar nerve injury and mandibular fracture are the main indications for this approach. Herein, we describe a case series of coronectomy to highlight its indication in normal and oncological patients. Material and methods A total of 9 patients were submitted to coronectomy, 6 of them were oncological. Three patients were evaluated before head and neck radiotherapy (HNRT), 2 after HNRT and 1 before bone marrow transplantation. Results Mean age of the patients was 49 years, most of them male (n=7). Lower third molars were the main teeth that received this procedure, and al…

MolarBone marrow transplantationMandibular fractureMandibular canalDentistryInferior alveolar nerveTooth crown03 medical and health sciences0302 clinical medicineHead and neck radiotherapystomatognathic systemCoronectomymedicineimpacted teethpostoperative complicationoncological patients030223 otorhinolaryngologyGeneral Dentistrybusiness.industryResearchMean age030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]//purl.org/pe-repo/ocde/ford#3.02.14 [https]stomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASOdontostomatology for the Disabled or Special PatientsbusinessJournal of clinical and experimental dentistry
researchProduct

Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy

2019

Erbium 169Er is one of the most interesting radiolanthanides for new potential receptor-targeted β− therapy applications due to its low energy β− emissions, very low intensity ɣ rays and the possibility to use 68Ga or 44Sc as companion for diagnostic in a theranostics approach. Currently it can be produced in reactors through the neutron activation of highly enriched 168Er. The low specific activity of the produced carrier-added 169Er is limiting its use for receptor-targeted therapy. Nonetheless it is used for radiosynoviorthesis of small joints. The aim of this work is to develop a new large-scale production method for the supply of very high specific activity 169Er. Highly enriched 168Er…

Nuclear and High Energy PhysicsHIGH SPECIFIC ACTIVITIESMaterials scienceTargeted Radiotherapychemistry.chemical_elementLASER IONIZATION7. Clean energy030218 nuclear medicine & medical imaginglaw.inventionErbium03 medical and health sciences0302 clinical medicinePRECLINICAL STUDIESlaw[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]Production (economics)HIGH SPECIFIC ACTIVITYIrradiationInstrumentationComputingMilieux_MISCELLANEOUSATOM LASERSRadiochemistrySELECTIVE IONIZATIONNuclear reactorERBIUMRESONANT LASER IONIZATIONLARGE SCALE PRODUCTIONSchemistryHigh specific activityER-169030220 oncology & carcinogenesisSEPARATION EFFICIENCYTARGETED RADIOTHERAPYIONIZATIONSpecific activityRECEPTOR-TARGETED THERAPYNeutron activationNUCLEAR REACTORSNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
researchProduct

The FIRST experiment at GSI

2012

The FIRST (Fragmentation of Ions Relevant for Space and Therapy) experiment at the SIS accelerator of GSI laboratory in Darmstadt has been designed for the measurement of ion fragmentation cross-sections at different angles and energies between 100 and 1000 MeV/nucleon. Nuclear fragmentation processes are relevant in several fields of basic research and applied physics and are of particular interest for tumor therapy and for space radiation protection applications. The start of the scientific program of the FIRST experiment was on summer 2011 and was focused on the measurement of 400 MeV/nucleon 12C beam fragmentation on thin (8 mm) graphite target. The detector is partly based on an alread…

Nuclear and High Energy PhysicsIon beamPhysics::Instrumentation and Detectorsmedicine.medical_treatmentNuclear physics[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]ScintillatorElementary-particleFIRST7. Clean energy01 natural sciencesParticle detectorWire chamberNuclear physicsDipole magnetFragmentationPARTICLE THERAPYhadrontherapy; fragmentation; nuclear physics; elementary-particle; instrumentation; experimental methodsHadrontherapy0103 physical sciencesmedicineNeutron detectionddc:530Gaseous detectorION-BEAM010306 general physicsNuclear ExperimentDETECTORInstrumentationGEANT4PARTICLE THERAPY; FLUKA CODE; ION-BEAM; FRAGMENTATION; BENCHMARKING; RADIOTHERAPY; TRANSPORT; DETECTOR; GEANT4; FIRSTPhysicsParticle therapyTime projection chamber010308 nuclear & particles physicsExperimental methodsDetectorScintillatorTRANSPORTSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)Hadrontherapy; Fragmentation; Nuclear physics; Elementary-particle; Experimental methods; InstrumentationFLUKA CODEBENCHMARKINGElementary-particle; Experimental methods; Fragmentation; Hadrontherapy; Instrumentation; Nuclear physics; Instrumentation; Nuclear and High Energy PhysicsRADIOTHERAPY
researchProduct

Analysis of the response of PVA-GTA Fricke-gel dosimeters with clinical magnetic resonance imaging

2018

Abstract Fricke gel dosimeters produced with a matrix of Poly-vinyl alcohol (PVA) cross-linked with glutaraldehyde (GTA) were analyzed with magnetic resonance imaging (MRI). Previous studies based on spectrophotometry showed valuable dosimetric features of these gels in terms of X-ray sensitivity and diffusion of the ferric ions produced after irradiation. In this study, MRI was performed on the gels at 1.5 T with a clinical scanner in order to optimize the acquisition parameters and obtain high contrast between irradiated and non-irradiated samples. The PVA gels were found to offer good linearity in the range of 0–10 Gy and a stable signal for several hours after irradiation. The sensitivi…

Nuclear and High Energy PhysicsXylenol orangeMaterials scienceSettore ING-IND/20 - Misure E Strumentazione NucleariDose profileGlutaraldehydeImaging phantom030218 nuclear medicine & medical imagingMatrix (chemical analysis)Gel dosimeter03 medical and health scienceschemistry.chemical_compoundMagnetic resonance imaging0302 clinical medicineNuclear magnetic resonanceIrradiationGlutaraldehydeùInstrumentationPoly-vinyl alcoholX-ray radiotherapyDosimeterSettore FIS/01 - Fisica SperimentaleSettore FIS/07 - Fisica Applicata(Beni Culturali Ambientali Biol.e Medicin)chemistry030220 oncology & carcinogenesisIonization chamberAgaroseGel dosimeter; Glutaraldehyde; Magnetic resonance imaging; Poly-vinyl alcohol; X-ray radiotherapy; Nuclear and High Energy Physics; InstrumentationSettore MED/36 - Diagnostica Per Immagini E RadioterapiaNuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
researchProduct

Stereotactic Radiotherapy for the Treatment of Patients With Oligo-progressive Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth …

2020

Aim This retrospective observational study evaluated the role of hypo-fractionated stereotactic radiotherapy (SRT) in patients with oligo-progressive metastatic renal cell carcinoma (mRCC) treated with first-line oral tyrosine kinase inhibitors (TKI). Data on local control, delay of further progression, and safety are reported. Patients and methods Between January 2010 and December 2016, 28 patients with mRCC who showed oligo-progressive disease while receiving first-line pazopanib were treated with hypofractionated SRT to progressive metastatic sites to delay the change of systemic therapy. First and second progression-free survival (PFS-1 and PFS-2) were recorded, as well as objective res…

OncologyAdultMaleCancer Researchmedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentTyrosine-kinase inhibitorDisease-Free SurvivalMetastasisPazopanibRenal cell carcinomaInternal medicinetyrosine kinase inhibitorsmedicinepazopanibmetastasisHumansNeoplasm MetastasisCarcinoma Renal CellProtein Kinase InhibitorsAgedRetrospective Studiesbusiness.industryCarcinomaRenal CellRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseasemetastasis; pazopanib; Renal cell carcinoma; stereotactic radiotherapy; tyrosine kinase inhibitors; Adult; Aged; Carcinoma Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Retrospective StudiesRenal cell carcinomaKidney NeoplasmsRadiation therapyOncologyToxicitystereotactic radiotherapyFemalebusinessTyrosine kinasemedicine.drug
researchProduct

Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in…

2017

Background The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to wh…

OncologyAdultMalemedicine.medical_specialtyautologous stem cell transplantationAdolescentLymphomaMedizinprimary CNS lymphoma whole brain radiotherapy autologous stem cell transplantationPhases of clinical researchThioTEPATransplantation AutologousDisease-Free SurvivalCentral Nervous System Neoplasms03 medical and health sciencesYoung Adult0302 clinical medicineAutologous stem-cell transplantationprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal ArticleMedicineHumansAgedManchester Cancer Research CentreDose-Response Relationship Drugbusiness.industryResearchInstitutes_Networks_Beacons/mcrcInduction chemotherapyBrainHematologyMiddle AgedCombined Modality Therapy3. Good healthSurgeryTransplantationRegimenMethotrexate030220 oncology & carcinogenesiswhole brain radiotherapyRituximabFemalebusiness030215 immunologymedicine.drugStem Cell Transplantation
researchProduct

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

2011

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage…

OncologyCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentDiseasechemotherapyDeoxycytidinelaw.inventionCarboplatinRandomized controlled trialNon-small cell lung cancerlawCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsPostoperative radiotherapyStage (cooking)Non-Small-Cell LungSurveyVinorelbineOncologyChemotherapy AdjuvantAdjuvantmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPaclitaxelnon-small cell lung cancer; adjuvant; Survey; chemotherapyVinblastineadjuvantInternal medicinemedicineHumansLung cancerNeoplasm StagingCisplatinAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryCarcinomamedicine.diseaseGemcitabineSurgeryAdjuvant chemotherapyRadiation therapyLung NeoplasmRegimenHealth Care SurveysAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; SurveyAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; Survey; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy Adjuvant; Vinblastine; Vinorelbine; Health Care Surveys; Oncology; Pulmonary and Respiratory Medicine; Cancer ResearchRadiotherapy AdjuvantCisplatinbusiness
researchProduct